Postoperative Identification of Tumour Cells at the Lumpectomy Site of Patients With Early Breast Cancer

Official Title

Postoperative Identification of Tumour Cells at the Lumpectomy Site of Patients With Early Breast Cancer

Summary:

For early breast cancer, local surgery followed by breast radiation is a standard local treatment. It has been found that the original primary tumour site, the lumpectomy site, is the commonest location of local relapse. The researchers think that such relapse occurs because of persistent tumour cells (PTCs) at the lumpectomy site even when conventional pathology reports indicate complete resection with clear margins. The researchers propose to analyze the lumpectomy fluid (seroma) of patients who are one to six weeks post-surgery for the presence or absence of tumour cells using new technology. Results of this study may help identify women who may have increased local relapse risk beyond that suggested by conventional pathology and clinical features; it may also help identify women at very low risk of local relapse who could avoid any additional treatment after local surgery.

Trial Description

Primary Outcome:

  • Identification of Persistent Tumour Cells (PTCs)

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society